ECTRIMS 2022 | The association between serum/CSF biomarkers and OCT measures in CIS patients

Angela Vidal-Jordana, MD, PhD, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d’Hebron University Hospital, Barcelona, Spain, and her team investigated the association of optical coherence tomography (OCT) measures with serum/CSF biomarkers, including neurofilament light chain (NfL), glial fibrillary acid protein (GFAP) and chitinase-3-like 1 protein (CHI3L1), in clinically isolated syndrome (CIS) patients. In CIS, the earliest stage of multiple sclerosis, these biomarkers have separately been shown to be associated with disease characteristics; however, little is understood about their interactions with each other. These results showed that serum/CSF biomarkers were not associated with OCT measures, suggesting that these retinal and biological biomarkers are probably measuring different aspects of the disease. Dr Vidal-Jordana now wants to investigate if these biomarkers can predict retinal integrity later in the disease course. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.